Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 6, Pages 2306-2315Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61319
Keywords
-
Categories
Funding
- NIH [R01MH079103, R01DA021336, T32GM07281, R01NS058505]
- University of Chicago Diabetes Research and Training Center [P60 DK020595]
Ask authors/readers for more resources
Glyoxalase 1 (Glo1) expression has previously been associated with anxiety in mice; however, its role in anxiety is controversial, and the underlying mechanism is unknown. Here, we demonstrate that GLO1 increases anxiety by reducing levels of methylglyoxal (MG), a GABA(A) receptor agonist. Mice overexpressing Glo1 on a Tg bacterial artificial chromosome displayed increased anxiety-like behavior and reduced brain MG concentrations. Treatment with low doses of MG reduced anxiety-like behavior, while higher doses caused locomotor depression, ataxia, and hypothermia, which are characteristic effects of GABA(A) receptor activation. Consistent with these data, we found that physiological concentrations of MG selectively activated GABA(A) receptors in primary neurons. These data indicate that GLO1 increases anxiety by reducing levels of MG, thereby decreasing GABA(A) receptor activation. More broadly, our findings potentially link metabolic state, neuronal inhibitory tone, and behavior. Finally, we demonstrated that pharmacological inhibition of GLO1 reduced anxiety, suggesting that GLO1 is a possible target for the treatment of anxiety disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available